Mechanism of endothelium-dependent vasorelaxation evoked by lysophosphatidylcholine

Hypertension Research

Volumn 21, Issue 3, 1998, Pages 137-145

  Hirayama, Tomoya ^a   Ogawa, Yuji ^a   Tobise, Katsuyuki ^a   Kikuchi, Kenjiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Endothelium derived nitric oxide; Lysophosphatidylcholine; Platelet activating factor

Indexed keywords

2 [N (2 METHOXY 3 OCTADECYLCARBAMOYLOXYPROPOXYCARBONYL)ACETAMIDOMETHYL] 1 ETHYLPYRIDINIUM CHLORIDE; INDOMETACIN; LYSOPHOSPHATIDYLCHOLINE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; MALE; MESENTERIC ARTERY; NONHUMAN; RAT; TACHYPHYLAXIS; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0031666577     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.21.137     Document Type: Article

References (25)

1. Hans UW: Cytolytic and membrane-perturbing properties of lysophosphatidylcholine. Biochim Biophys Acta 1979; 559: 259-287.
2. Ralph AK, Donald SO, William EM, et al: Identification of NaK-ATPase inhibitors in human plasma as nonesterified fatty acids and lysophospholipids. J Biol Chem 1986; 261: 11704-11711.
3. Gary JN: The phospholipid composition of plasma in various mammalian species. Lipids 1967; 2: 323-328.
4. Ari H, Darrell RM, Erik F, et al: Properties of detergents. Methods Enzymol 1979; LVI: 734-749.
5. Buckalew VM, Morris M: Plasma inhibitors of Na, K-ATPase: relation to salt balance and hypertension. Klin Wochenschr 1987; 65: 133-138.
6. Rauch AL, Buckalew VM: Lysophospholipids are natriuretic and diuretic in rats. Am J Physiol 1988; 254: F824-F827.
7. Rauch AL, Buckalew VM: Plasma volume expansion increases lysophosphatidylcholine and digitalis-like activity in rat plasma. Life Sci 1988; 42: 1189-1197.
8. Rauch AL, Buckalew VM: Characterization of a competitive and reversible ligand to E2 conformation of Na, K ATPase molecule. Biochem Biophys Res Commun 1988; 150: 648-654.
9. Bing RJ, Saeed M: The role of lysolecithin in the relaxation of vascular smooth muscle. Biosci Rep 1987; 7: 783-789.
10. Menon NK, Saito T: Correlation of lysophosphatidylcholine-induced vs spontaneous relaxation to cyclic GMP levels in rabbit thoracic aorta. Life Sci 1989; 44: 611-618.
11. Saito T, Wolf A, Menon NK, et al: Lysolecithins as endothelium-dependent vascular smooth muscle relaxants that differ from endothelium-derived relaxing factor (nitric oxide). Proc Natl Acad Sci USA 1988; 85: 8246-8250.
12. Wolf A, Saito T: Effects of lysophosphatidylcholine on atherosclerotic rabbit arteries. Atherosclerosis 1989; 80: 81-89.
13. Menon NK, Pataricza J, Zehetgruber M, et al: A model to study physiological activation of phospholipase A2 and vasorelaxation by lysophosphatidylcholine. Life Sci 1990; 47: 1941-1948.
14. Hirayama T, Ogawa Y, Tobise K, et al: Mechanism of endothelium-dependent vasorelaxation to lysophosphatidylcholine. Jpn J Pharmacol 1992; 58 (Suppl II): 391P.
15. Schmidt HHHW, Nau H: Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol 1988; 154: 213-216.
16. Rees DD, Moncada S: A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 1989; 96: 418-424.
17. Shigenobu K, Masuda Y, Kasuya Y, et al: Platelet activating factor analogues: lack of correlation between their activities to produce hypotension and endothelium-mediated vasodilation. J Pharmacobiodyn 1985; 8: 128-133.
18. Shigenobu K, Tanaka Y: Potentiation by bovine serum albumin (BSA) of endothelium-dependent vasodilator response to acetyl-glyceryl ether phosphorylcholine (AGEPC). J Pharmacobiodyn 1987; 10: 220-228.
19. Chiba Y, Mikoda N, Ito K, et al: Endothelium-dependent relaxant action of platelet activating factor in the rat mesenteric artery. Naunyn Schmiedebergs Arch Pharmacol 1990; 341: 68-73.
20. Kamata K, Mori T, et al: Endothelium-dependent vasodilator effects of platelet activating factor on rat resistance vessels. Br J Pharmacol 1989; 98: 1360-1364.
21. Verghese MW: Role of a guanine nucleotide regulatory protein in the activation of phospholipase C by different chemoattractants. J Immunol 1987; 138: 4374.
22. Nakashima S, Suganuma A, Sato M, et al: Mechanism of arachidonic acid liberation in platelet-activating factor-stimulated human polymorphonuclear neutrophils. J Immunol 1989; 143: 1295-1302.
23. O'Flaherty JT: Platelet-activating factor in Snyder F (ed): Mechanism of cellular activation in platelet activating factor and related lipid mediators. New York, Plenum Press, 1987, pp283-298.
24. Terashita Z, Imura Y, Nishikawa K, et al: CV-6209, A highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther 1987; 242: 263-268.
25. Bussolino F, Camussi G: Platelet-activating factor produced by endothelial cells A molecule with autocrine and paracrine properties. Eur J Biochem 1995; 229: 327-337.